Solvias Acquires Cergentis to Bolster Biologics and Cell & Gene Therapy Capabilities
![](/46/pdcnewsitem/11/87/95/PR_solvias_20220712_LI_exp.png)
Cergentis enables Solvias to provide customers with proprietary technology and knowledge steeped in fast-evolving genomic techniques that support effective decision-making and R&D program design.
News Summary
- Solvias, one of the world’s leading independent pharmaceutical
testing and manufacturing companies, has acquired Netherlands-based Cergentis to
bolster its biologics and cell & gene therapy testing capabilities.
- With global sales of cell & gene therapies projected to accelerate
at a 63% compound annual growth rate, more researchers require sophisticated solutions
to validate the safety & efficacy of these advanced new therapies.
- Cergentis enables Solvias to provide customers with proprietary
technology and knowledge steeped in fast-evolving genomic techniques that support
effective decision-making and R&D program design.
![Solvias AG](https://www.cphi-online.com/Z7w4DUjHCeQPYEm-comp247958.png)
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance